- Ukwelashwa
- Ubufakazi
- I-Neuroblastoma
- Isimila Esiqinile
- Ubufakazi
- I-TILS
- Ukwelashwa Kwamaseli e-NK
- I-Myasthenia Gravis (MG)
- I-Acute Lymphoblastic Leukemia (B-ALL)
- I-Systemic Lupus Erythematosus (SLE)
- I-Acute Lymphoblastic Leukemia (T-ALL)
- I-Non-Hodgkin Lymphoma (NHL)
- I-Multiple Myeloma (MM)
- I-Diffuse Large B-cell Lymphom
- I-B-lymphocytic Leukemia
- I-Myeloma
Ukwelashwa kwe-CAR-T kwe-Non-Hodgkin Lymphoma (NHL)
Ukubuka konke
I-Non-Hodgkin Lymphoma (NHL) iyiqembu elihlukahlukene lomdlavuza wegazi elivela ohlelweni lwe-lymphatic, elinamaqembu ahlukahlukene, kufaka phakathi ama-lymphoma e-B-cell kanye nama-T-cell. Phakathi kwalawa, I-Diffuse Large B-Cell Lymphoma (DLBCL) uhlobo oluvame kakhulu nolunolaka lwe-B-cell NHL. Naphezu kwentuthuko kwezokwelapha ngamakhemikhali kanye ne-immunotherapy, iziguli eziningi ezine-NHL ephinde yagula noma engaphili kahle zilwa nezinketho zokwelapha ezilinganiselwe. Ukwelashwa kwe-CAR-T inikeza indlela entsha, enikeza ithemba ezigulini ezine-lymphoma engasabelanga ekwelashweni kwendabuko.
Kuyini i-CAR-T Therapy ye-NHL?
Ukwelashwa nge-CAR-T (Chimeric Antigen Receptor T-cell) kuyindlela entsha yokwelapha nge-immunotherapy ehilela ukuguqula ama-T-cell esiguli ukuze aveze i-receptor ehlasela amaseli anomdlavuza. Ku-NHL, ukwelashwa nge-CAR-T kuhlose kakhulu I-CD19 futhi I-CD20 Ama-antigen kuma-B-cell, avame ukutholakala kumaseli e-malignant lymphoma. Ngokuthuthukisa ikhono lama-T-cell lokubona nokuhlasela lawa maseli omdlavuza, ukwelashwa kwe-CAR-T kunikeza inketho yokwelapha ephumelelayo yeziguli ezine-lymphoma ephinde yabuya noma engaphikisi.
Izinzuzo Eziyinhloko Zokwelashwa Kwe-CAR-T Kwe-NHL
- Isebenza kahle kwi-NHL ephinde yabuyela esimweni sayo sokuqala kanye ne-Refractory: Ukwelashwa kwe-CAR-T kubonise ukusebenza kahle okukhulu ezigulini ezine-DLBCL nezinye izinhlobo ze-B-cell NHL ezingazange zisabele emigqeni eminingi yokwelashwa.
- Ukunemba Okuqondiwe: Ukwelashwa kuhlose amaseli e-B anomdlavuza ngaphandle kokulimaza amaseli anempilo, kunciphisa imiphumela emibi evame ukuhlotshaniswa nezindlela zokwelapha zendabuko.
- Ukwelashwa Okuqondene NakhoUkwelashwa kwe-CAR-T kusebenzisa amaseli e-T esiguli, okunikeza indlela yokwelapha eyenziwe ngokwezifiso ehambisana nesimo esithile somuntu.
- Kungenzeka Ukuthethelelwa Kwesikhathi EsideIziguli eziningi ziye zathola ukuphulukiswa okuphelele noma okuyingxenye ngemva kokwelashwa nge-CAR-T, kanti ezinye ziyaqhubeka nokusinda isikhathi eside, ngisho nangemva kokwelashwa ngamakhemikhali kaningi.
Inqubo Yokwelapha
- Iqoqo lamaseli e-TAmaseli e-T aqoqwa egazini lesiguli ngenqubo ebizwa ngokuthi i-leukapheresis, efana nokunikelwa kwegazi.
- Ubunjiniyela bamaseli e-T: Elabhorethri, ama-T-cell aqoqiwe aguqulwa ngokwezakhi zofuzo ukuze aveze ama-receptor aqondisa ama-antigen athile afana I-CD19 noma I-CD20 kutholakala kumaseli e-lymphoma.
- Ukufakwa kwe-CAR-T: Uma ama-T-cell esekhulisiwe futhi eguquliwe, aphinde afakwe egazini lesiguli ukuze ahlasele amaseli e-lymphoma.
- Ukuqapha Nokubuyisela Esimeni: Ngemva kokufakwa, iziguli ziqashwe ngeso lokhozi imiphumela emibi, njenge-cytokine release syndrome (CRS) kanye nobuthi be-neurotoxicity, kokubili okungalawulwa ngokungenelela okufanele kwezokwelapha.
Kungani Kufanele Ukhethe Ukwelashwa Kwe-CAR-T Kwe-BIOOCUS Kwe-NHL?
- Ubuchwepheshe be-CAR-T obusezingeni eliphezulu: I-BIOOCUS isebenzisa ubuchwepheshe be-CAR-T obusezingeni eliphezulu ukuze inikeze ukwelashwa okuthuthukisiwe kakhulu nokuphumelelayo kwe-NHL, isebenzisa ucwaningo lwakamuva ukuqinisekisa imiphumela emihle kakhulu.
- Ithimba Lochwepheshe Begazi: Ithimba lethu lezifundo eziningi zodokotela begazi, odokotela bezifo zomdlavuza, kanye nochwepheshe be-immunotherapy basebenzisana ukuhlinzeka ngezinhlelo zokwelapha ezenzelwe umuntu ngamunye.
- Impumelelo Efakazelwe Ekwelapheni i-DLBCL: I-BIOOCUS yelaphe iziguli eziningi ze-NHL ngokwelashwa kwe-CAR-T, yathola izimpendulo eziphawulekayo, okuhlanganisa ukuphulukiswa okuphelele kanye nokusinda isikhathi eside, ikakhulukazi ezigulini ezine-DLBCL ephinde yagula noma engalapheki.
- Ukusekelwa Okuphelele KwesiguliKusukela ekubonisaneni kokuqala kuya ekunakekelweni kwangemva kokwelashwa, i-BIOOCUS inikeza ukwesekwa okuphelele ezigulini zamazwe ngamazwe, iqinisekisa uhambo olubushelelezi nolusekelayo kulo lonke inqubo yazo yokwelashwa.
Ubufakazi Bezokwelapha kanye Namazinga Empumelelo
-
Ukwelashwa kwe-CAR-T kwe-NHL, ikakhulukazi kwe-DLBCL, kubonise imiphumela emihle kakhulu ezivivinyweni zezokwelapha kanye nokusetshenziswa kwangempela. Ezigulini eziye zadlula emigqeni eminingi yokwelashwa ngaphandle kwempumelelo, ukwelashwa kwe-CAR-T kuye kwabonakala kuyindlela esindisa impilo.
- Indaba Yesiguli: I-Diffuse Large B-Cell Lymphoma (DLBCL)—Ukululama Okumangalisayo Ngemva Kokwelashwa Nge-CAR-T
- Impumelelo Yezokwelapha: Ukwelashwa kwe-CAR-T kwe-DLBCL Ebuye Yaphela—Indlela Yokuxolelwa Okuphelele
- I-DLBCL Emelana Nemigqa Eminingi: Ucwaningo Lwecala Lokusebenza Kokwelashwa Kwe-CAR-T ku-Advanced Lymphoma
Lezi zifundo ziqokomisa amandla okuguqula ukwelashwa kwe-CAR-T ezigulini ezine-NHL, ikakhulukazi lezo ezine-DLBCL enamandla futhi engamelani nemigqa eminingi. Iziguli eziningi ziye zathola ukuphulukiswa kwesikhathi eside futhi seziphinde zathola izinga lempilo ngemva kokwelashwa.
Idatha Yezokwelapha
Izinkomba ze-CD19+20CAR-T:Iziguli ezine-B-cell non-Hodgkin's lymphoma
| Izinga le-CR lenyanga eyodwa | Izinga le-PR lenyanga eyodwa | Isilinganiso se-OR senyanga eyodwa | I-CRS≥3 | I-CRES≥3 |
| 71.95% (59/82) | 25.6（21/82） | 97.55（80/82） | 12.19% (10/82) | 0 |
Izinkomba ze-CD19+22CAR-T:Ukwelashwa kweziguli ezine-CD19 eziphinde zabuyela emuva futhi ezingasabeli kahle i-B-lymphocytic leukemia
| Izinga le-CR lenyanga eyodwa | Izinga le-PR lenyanga eyodwa | Isilinganiso se-OR senyanga eyodwa | I-CRS≥3 | I-CRES≥3 |
| 92.1%（35/38） | 7.9%（3/38） | 100% (38/38) | 15.79% (6/38) | 0 |
Izinkomba ze-BCMACAR-T:Ukwelashwa kwe-myeloma eminingi ephinde yabuya futhi engaphikisi
| Izinga le-CR lenyanga eyodwa | Izinga le-PR lenyanga eyodwa | Isilinganiso se-OR senyanga eyodwa | I-CRS≥3 | I-CRES≥3 |
| 72.41% (21/29) | 27.59%（8/29） | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.